Please assess the completion status of the following clinical trial:

Trial Title: First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, non-smoking male subjects~* BMI (body mass index) between 18.0 and 28.0 kg/m\^2, both incl.~* Body weight 50 to 100 kg, both incl.~Exclusion Criteria:~* Strenuous exercise within 4 days prior to dosing~* Receipt of any investigational medicinal product within 3 months prior to randomisation

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Single dose (SD) (Type: EXPERIMENTAL): Single dose administered s.c. (subcutaneously, under the skin). Escalation to the next dose level will be based on safety evaluation
- Multiple dose (MD) (Type: EXPERIMENTAL): Multiple doses administered s.c. (subcutaneously, under the skin). All subjects will be dosed four times with a dosing frequency of once weekly. Escalation to the next dose level will be based on safety evaluation

Based on this trial design, predict the completion outcome and termination type (if applicable).